RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing
News | 03. 23. 2016
Envisia Therapeutics
RESEARCH TRIANGLE PARK, NC – March 23, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced a $16.5 million investment from existing investors to support the accelerated development of the Company's pipeline of innovative extended-release ocular therapies for the three leading causes of preventable vision loss and blindness.
